Biosergen AB announced that the company's abstract about the drug candidate BSG005, which was presented at the 11th Trends in Medical Mycology, on October 21, 2023, is now publicly available. The abstract presentation, given by Biosergen's COO Tine Olesen, laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the majority of adverse events being infusion-related in the single ascending dose part of the trial and phlebitis in the multi ascending dose part of the trial, and no severe adverse events were seen in the study.

Also, basic pharmacovigilance parameters were established. Currently, Biosergen and its partner Alkem Laboratories Ltd. are preparing a Phase 2 clinical trial in India. The trial will enrol patients suffering from severe fungal infections such as mucormycosis, aspergillosis, and candidiasis.

Based on the safety and efficacy profile demonstrated in the preclinical studies and the phase I trials, as also published in the above-mentioned abstract, BSG005 may provide a suitable treatment option for these patients.